[Conservative treatment of arteriosclerosis obliterans of the lower limbs].
D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001162:Arteriosclerosis Obliterans / Q000628:therapy*; D011464:Epoprostenol / Q000096:biosynthesis; D005081:Exercise Therapy; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007866:Leg / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000187:drug effects; D013268:Stimulation, Chemical; D014665:Vasodilator Agents / Q000627:therapeutic use
D043925:Angiogenesis Inducing Agents; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014665:Vasodilator Agents; D011464:Epoprostenol
Postepowanie zachowawcze w miazdzycy zarostowej tetnic kończyn dolnych.